← Back to patent-cliff list
Linafexor
Tier C — Watch / tradeLinafexor
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FXR
Indications (approved)：Sclerosing cholangitis, Biliary cirrhosis, Non-alcoholic steatohepatitis, Overweight, Obesity, Inflammatory bowel disease
Regional status
US
Phase II
2023-02-10
EU
-
China
Phase III
2025-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Linafexor?
Approved indications include: Sclerosing cholangitis, Biliary cirrhosis, Non-alcoholic steatohepatitis, Overweight, Obesity, Inflammatory bowel disease.
When does the Linafexor patent expire?
No public expiry year is available for Linafexor yet; this page updates once verified.
How do I get a quote for Linafexor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29